Funding
Oncos Therapeutics, of Helsinki, Finland, which is developing cancer therapeutics based on oncolytic viruses, has completed a €4 million investment from HealthCap.
After treating 200 late-stage cancer patients since 2007, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. “This is the first step to turn our Advanced Therapy Access Programme results into cancer therapeutics,” said Pekka Simulate, CEO and co-founder.
“The results have been strong for late stage solid tumour cancers, where routine therapies have failed. We are confident that when treating earlier-stage patients, our oncolytic virus therapy will prove even more significant,” Abseil Hemminge, Chief Scientific Officer and co-founder.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.